Can-Fite Phase III Trials in RA, Psoriasis Expected to Commence in 2016; Planning Phase II Trial for New indication in NASH

Can-Fite BioPharma Ltd. (NYSE MKT:

) today announced its anticipated clinical milestones for calendar year 2016.  Q1 2016  Rheumatoid Arthritis Phase III EMA Submission for CF101 In the first quarter of 2016, Can-Fite plans to file its Phase III protocol with the European Medicines Agency (EMA) for CF101 in the treatment of rheumatoid arthritis. Initiation of patient enrollment is anticipated in the second or third quarter of 2016.  Can-Fite recently filed a trial protocol with the institutional review board (IRB) of Barzilai Medical Center in Israel, one of the planned clinical sites for the international trial to be conducted in Israel, Europe, Canada and the U.S. The Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of CF101 administered orally twice daily for 16